Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biodesix Inc
(NQ:
BDSX
)
1.440
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
1.440
Bid (Size)
1.440 (1)
Ask (Size)
1.550 (10)
Prev. Close
1.440
Today's Range
1.440 - 1.440
52wk Range
1.030 - 2.210
Shares Outstanding
78,614,114
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center
March 25, 2024
From
Biodesix, Inc.
Via
Business Wire
Biodesix Reports 65% Growth In Lung Diagnostic Test Volume In Q4
March 02, 2024
Biodesix Inc. reported strong Q4 performance, with significant revenue growth.
Via
Talk Markets
Performance
YTD
-19.10%
-19.10%
1 Month
-5.88%
-5.88%
3 Month
-20.88%
-20.88%
6 Month
-6.49%
-6.49%
1 Year
-16.28%
-16.28%
More News
Read More
12 Health Care Stocks Moving In Friday's Pre-Market Session
March 01, 2024
Via
Benzinga
Earnings Scheduled For March 1, 2024
March 01, 2024
Via
Benzinga
Biodesix: Q4 Earnings Insights
March 01, 2024
Via
Benzinga
Biodesix's Earnings Outlook
February 29, 2024
Via
Benzinga
Recap: Biodesix Q3 Earnings
November 07, 2023
Via
Benzinga
Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights
March 01, 2024
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference
February 26, 2024
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024
February 16, 2024
From
Biodesix, Inc.
Via
Business Wire
3 Penny Stocks to Turn $999 Into $1 Million: January 2024
January 26, 2024
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Biodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw Method
November 14, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Participate in Two Upcoming Investor Conferences in November
November 09, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Third Quarter 2023 Results and Highlights
November 07, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023
October 24, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting
October 03, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer
September 07, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Participate in Two Upcoming Investor Conferences in September
September 05, 2023
From
Biodesix, Inc.
Via
Business Wire
Kingstone Companies And 3 Other Stocks Under $2 Insiders Are Buying
August 24, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer
August 22, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Second Quarter 2023 Results and Highlights
August 07, 2023
From
Biodesix, Inc.
Via
Business Wire
Top 5 Health Care Stocks That May Crash In Q3
August 07, 2023
Via
Benzinga
Biodesix to Participate in the Canaccord Genuity 43rd Annual Growth Conference
August 01, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023
July 24, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules
July 12, 2023
From
Biodesix, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.